Acura Pharmaceuticals (STU:HD4B) WACC %:8.29% (As of Jul. 03, 2026)


STU:HD4B Acura Pharmaceuticals Inc STU:HD4B
16 GF Score
Price €0.20
View Full Analysis

What is Acura Pharmaceuticals WACC %?

Acura Pharmaceuticals STU:HD4B 16 WACC % is 8.29% as of Jul. 03, 2026. GuruFocus rates STU:HD4B with a GF Score™ of 16/100.

As of today (2026-07-03), Acura Pharmaceuticals's weighted average cost of capital is 8.29%%. Acura Pharmaceuticals's ROIC % is 0.00% (calculated using TTM income statement data). Acura Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Acura Pharmaceuticals  (STU:HD4B) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Acura Pharmaceuticals's weighted average cost of capital is 8.29%%. Acura Pharmaceuticals's ROIC % is 0.00% (calculated using TTM income statement data). Acura Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Acura Pharmaceuticals WACC % Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals WACC % Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.97 12.88 7.81 6.18 0.00

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.18 5.26 4.16 5.56 0.00

STU:HD4B vs VFRM, THCT, CBGL: WACC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acura Pharmaceuticals WACC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's WACC % distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's WACC % falls into.


STU:HD4B
16GF Score
Acura Pharmaceuticals Inc STU:HD4B
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Acura Pharmaceuticals's market capitalization (E) is €1.148 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2021, Acura Pharmaceuticals's latest one-year quarterly average Book Value of Debt (D) is €2.3188 Mil.
a) weight of equity = E / (E + D) = 1.148 / (1.148 + 2.3188) = 0.3311
b) weight of debt = D / (E + D) = 2.3188 / (1.148 + 2.3188) = 0.6689

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.485%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Acura Pharmaceuticals's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.485% + 1 * 6% = 10.485%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Dec. 2021, Acura Pharmaceuticals's interest expense (positive number) was €0.167 Mil. Its total Book Value of Debt (D) is €2.3188 Mil.
Cost of Debt = 0.167 / 2.3188 = 7.202%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -0.736 = 0%.

Acura Pharmaceuticals's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.3311*10.485%+0.6689*7.202%*(1 - 0%)
=8.29%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 8.29% mean?
Acura Pharmaceuticals (STU:HD4B) has a WACC % of 8.29% as of Jul. 03, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' WACC % too high?
Acura Pharmaceuticals' current WACC % is 8.29%. The Drug Manufacturers industry median WACC % is 8.86. Acura Pharmaceuticals' value of 8.29% is 6.4% below this industry median. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' WACC % compare to VFRM and THCT?
Acura Pharmaceuticals' WACC % of 8.29% can be compared against companies in the Drug Manufacturers industry. The industry median WACC % is 8.86. Acura Pharmaceuticals' value of 8.29% is 6.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 8.86, based on 1,019 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acura Pharmaceuticals's current WACC % of 8.29% is 6.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Acura Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median WACC % is 8.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acura Pharmaceuticals's current WACC % is 8.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current WACC % of 8.29%. The current WACC % is 8.29% and 6.4% below the Drug Manufacturers industry median of 8.86. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current WACC % is 8.29% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for STU:HD4B

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price